NeoTYPE Cancer Profiles

NeoTYPE™ Cancer Profiles are multi-method test panels, custom-designed for a specific tumor type, that identify the genetic changes most significant to therapy decisions, prognosis, and clinical research. Read more.


123
Methodology Test Name Test Description Results per page:
NeoTYPE NeoTYPE™ AML Favorable-Risk Profile This test is performed by sequencing of select exons of the genes FLT3 and KIT. Test orders include summary interpretation of all results together. Individual genes from a validated list of myeloid genes can be added-on. In addition, the genes listed above can be ordered separately and will be reported individually without summary interpretation.
NeoTYPE NeoTYPE™ AML Prognostic Profile This test is performed by sequencing of select exons of the genes listed. ASXL1, BRAF, CEBPA, DNMT3A, ETV6, FLT3, HRAS, IDH1, IDH2, JAK2 V617F, JAK2 Exon 12+14, KRAS, MLL, NPM1, NRAS, PDGFRA, PHF6, PTPN11, RUNX1, SETBP1, TET2, TP53 and WT1. Individual genes from a validated list of myeloid genes can be added-on. Test orders include summary interpretation of all results together. Any tests may be ordered separately; these will be reported individually without summary interpretation. The AML Prognostic Profile may also be ordered as reflex after intermediate cytogenetics in the AML Reflex Panel (see separate AML Reflex Panel listing).
NeoTYPE NeoTYPE™ Brain Tumor Profile This test is performed by the sequencing of select exons of the genes listed unless another method is noted. ATRX, BRAF, CTNNB1, EGFR, ERBB2, ERBB4, IDH1, IDH2, MET, MGMT Promoter Methylation Analysis, PIK3CA, PTEN, SMO, TP53, 1p/19q Deletion FISH, BRAF FISH, MET FISH, MYC Amp FISH and PTEN FISH. Individual genes from a validated list of solid tumor genes can be added-on. Test orders include summary interpretation of all results together. FISH / Flow components of NeoTYPE Profiles may be ordered as "Tech-Only" by pathology clients who wish to perform the professional component. Any tests may be ordered separately; these will be reported individually without summary interpretation. Temporary Notice: BRAF FISH and MYC Amp FISH currently unavailable.
NeoTYPE NeoTYPE™ Breast Tumor Profile This test is performed by the sequencing of select exons of the genes listed unless another method is noted. BRAF, CTNNB1, EGFR, ERBB2, ERBB4, HRAS, KIT, KRAS, MET, NRAS, PIK3CA, PTEN, SMO, TP53, HER2 FISH, MET FISH, PTEN FISH. Individual genes from a validated list of solid tumor genes can be added-on. Test orders include summary interpretation of all results together. FISH / Flow components of NeoTYPE Profiles may be ordered as "Tech-Only" by pathology clients who wish to perform the professional component. Any tests may be ordered separately; these will be reported individually without summary interpretation.
NeoTYPE NeoTYPE™ Cancer Exome Profile The NeoTYPE Cancer Exome Profile is performed by massive parallel sequencing of the coding regions in 4813 different cancer related genes. Test orders include summary interpretation of all results together.
NeoTYPE NeoTYPE™ Cervical Tumor Profile This test is performed by the sequencing of select exons of the genes listed unless another method is noted. BRAF, CTNNB1, EGFR, ERBB2, ERBB4, HRAS, KRAS, MET, NOTCH1, NRAS, PDGFRA, PIK3CA, PTEN, SMO, TP53, MET FISH, PTEN FISH. Individual genes from a validated list of solid tumor genes can be added-on. Test orders include summary interpretation of all results together. FISH / Flow components of NeoTYPE Profiles may be ordered as "Tech-Only" by pathology clients who wish to perform the professional component. Any tests may be ordered separately; these will be reported individually without summary interpretation.
NeoTYPE NeoTYPE™ CLL Prognostic Profile This test is performed by the sequencing of select exons of the genes listed, plus the CLL FISH Panel and ZAP-70 flow cytometry as noted. IgVH Mutation, MYD88, NOTCH1, SF3B1, TP53. Individual genes from a validated list of myeloid genes can be added-on. Test orders include summary interpretation of all results together. FISH / Flow components of NeoTYPE Profiles may be ordered as "Tech-Only" by pathology clients who wish to perform the professional component. Any tests may be ordered separately; these will be reported individually without summary interpretation.
NeoTYPE NeoTYPE™ Colorectal Tumor Profile This test is performed by the sequencing of select exons of the genes listed unless another method is noted. BRAF, EGFR, HRAS, KIT, KRAS, MET, Microsatellite Instability (MSI), MLH1 Promoter Methylation, NOTCH1, NRAS, PDGFRA, PIK3CA, PTEN, SMO, TP53, MET FISH, PTEN FISH. Individual genes from the 48 gene Solid Tumor panel can be added-on. Test orders include summary interpretation of all results together. FISH / Flow components of NeoTYPE Profiles may be ordered as "Tech-Only" by pathology clients who wish to perform the professional component. Any tests may be ordered separately; these will be reported individually without summary interpretation.
NeoTYPE NeoTYPE™ Discovery Profile for Solid Tumors This test is performed by the sequencing of select exons of the genes listed unless another method is noted. ABL1, ABL2, ACVR1B, AKT1, AKT2, AKT3, ALK, AMER1 (FAM123B), APC, AR, ARAF, ARFRP1, ARID1A, ARID1B, ARID2, ASXL1, ATM, ATR, ATRX, AURKA, AURKB, AXIN1, AXL, BAP1, BARD1, BCL2, BCL2L1, BCL2L2, BCL6, BCOR, BCORL1, BLM, BRAF, BRCA1, BRCA2, BRD4, BRIP1, BTG1, BTK, C11orf30, CARD11, CBFB, CBL, CCND1, CCND2, CCND3, CCNE1, CD274, CD79A, CD79B, CDC73, CDH1, CDK12, CDK4, CDK6, CDK8, CDKN1A, CDKN1B, CDKN2A, CDKN2B, CDKN2C, CEBPA, CHD2, CHD4, CHEK1, CHEK2, CIC, CREBBP, CRKL, CRLF2, CSF1R, CTCF, CTNNA1, CTNNB1, CUL3, CYLD, DAXX, DDR2, DICER1, DNMT3A, DOT1L, EGFR, EP300, EPHA3, EPHA5, EPHA7, EPHB1, ERBB2, ERBB3, ERBB4, ERG, ERRFI1, ESR1, EZH2, FAM46C, FANCA, FANCC, FANCD2, FANCE, FANCF, FANCG, FANCL, FAS, FAT1, FBXW7, FGF10, FGF14, FGF19, FGF23, FGF3, FGF4, FGF6, FGFR1, FGFR2, FGFR3, FGFR4, FH, FLCN, FLT1, FLT3, FLT4, FOXL2, FOXP1, FRS2, FUBP1, GABRA6, GATA1, GATA2, GATA3, GATA4, GATA6, GID4 (C17orf39), GLI1, GNA11, GNA13, GNAQ, GNAS, GPR124, GRIN2A, GRM3, GSK3B, H3F3A, HGF, HNF1A, HRAS, HSD3B1, HSP90AA1, IDH1, IDH2, IGF1R, IGF2, IKBKE, IKZF1, IL7R, INHBA, INPP4B, IRF2, IRF4, IRS2, JAK1, JAK2, JAK3, JUN, KAT6A (MYST3), KDM5A, KDM5C, KDM6A, KDR, KEAP1, KEL, KIT, KLHL6, KMT2A (MLL), KMT2C (MLL3), KMT2D (MLL2), KRAS, LMO1, LRP1B, LYN, LZTR1, MAGI2, MAP2K1, MAP2K2, MAP2K4, MAP3K1, MCL1, MDM2, MDM4, MED12, MEF2B, MEN1, MET, MITF, MLH1, MPL, MRE11A, MSH2, MSH6, MTOR, MUTYH, MYC, MYCL (MYCL1), MYCN, MYD88, NF1, NF2, NFE2L2, NFKBIA, NKX2-1, NOTCH1, NOTCH2, NOTCH3, NPM1, NRAS, NSD1, NTRK1, NTRK2, NTRK3, NUP93, PAK3, PALB2, PARK2, PAX5, PBRM1, PDCD1LG2, PDGFRA, PDGFRB, PDK1, PIK3C2B, PIK3CA, PIK3CB, PIK3CG, PIK3R1, PIK3R2, PLCG2, PMS2, POLD1, POLE, PPP2R1A, PRDM1, PREX2, PRKAR1A, PRKCI, PRKDC, PRSS8, PTCH1, PTEN, PTPN11, QKI, RAC1, RAD50, RAD51, RAF1, RANBP2, RARA, RB1, RBM10, RET, RICTOR, RNF43, ROS1, RPTOR, RUNX1, RUNX1T1, SDHA, SDHB, SDHC, SDHD, SETD2, SF3B1, SLIT2, SMAD2, SMAD3, SMAD4, SMARCA4, SMARCB1, SMO, SNCAIP, SOCS1, SOX10, SOX2, SOX9, SPEN, SPOP, SPTA1, SRC, STAG2, STAT3, STAT4, STK11, SUFU, SYK, TAF1, TBX3, TERC, TERT (promoter only), TET2, TGFBR2, TNFAIP3, TNFRSF14, TOP1, TOP2A, TP53, TSC1, TSC2, TSHR, U2AF1, VEGFA, VHL, WISP3, WT1, XPO1, ZBTB2, ZNF217, ZNF703, ALK FISH, BRAF FISH, HER2 FISH, MET FISH, c-MYC FISH, PDGFRA FISH, PTEN FISH, RET FISH and ROS1 FISH. Test orders include summary interpretation of all results together.
NeoTYPE NeoTYPE™ Endometrial Tumor Profile This test is performed by the sequencing of select exons of the genes listed unless another method is noted. BRAF, EGFR, HRAS, KIT, KRAS, MET, Microsatellite Instability (MSI), NRAS, PDGFRA, PIK3CA, PTEN, PTPN11, SMO, TP53, MET FISH, PTEN FISH. Individual genes from a validated list of solid tumor genes can be added-on. Test orders include summary interpretation of all results together. FISH / Flow components of NeoTYPE Profiles may be ordered as "Tech-Only" by pathology clients who wish to perform the professional component. Any tests may be ordered separately; these will be reported individually without summary interpretation.
123